Dominik Höchli
Director/Board Member at MOLECULAR PARTNERS AG
Dominik Höchli active positions
| Companies | Position | Start | End |
|---|---|---|---|
| MOLECULAR PARTNERS AG | Director/Board Member | 21/04/2021 | - |
| Independent Dir/Board Member | 21/04/2021 | - | |
Catapult Therapeutics BV
 Catapult Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Catapult Therapeutics BV operates as a biopharmaceutical company which develops cancer treatments. It is developing CAP-100, a humanized anti-CCR7 antibody. The company was founded in 2015 and is headquartered in Lelystad, the Netherlands. | Chief Executive Officer | 01/01/2021 | - |
Career history of Dominik Höchli
Former positions of Dominik Höchli
| Companies | Position | Start | End |
|---|---|---|---|
| AbbVie AG | Corporate Officer/Principal | - | - |
Training of Dominik Höchli
| University of Bern | Doctorate Degree |
Statistics
International
| Switzerland | 4 |
| Netherlands | 2 |
Operational
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
| Doctorate Degree | 1 |
Sectoral
| Consumer Services | 2 |
| Health Technology | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| MOLECULAR PARTNERS AG | Health Technology |
| Private companies | 2 |
|---|---|
| AbbVie AG | |
Catapult Therapeutics BV
Catapult Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Catapult Therapeutics BV operates as a biopharmaceutical company which develops cancer treatments. It is developing CAP-100, a humanized anti-CCR7 antibody. The company was founded in 2015 and is headquartered in Lelystad, the Netherlands. | Commercial Services |
- Stock Market
- Insiders
- Dominik Höchli
- Experience
